We are live on ! Find out more
CRBU icon

Caribou Biosciences

131 hedge funds and large institutions have $46.5M invested in Caribou Biosciences in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 35 increasing their positions, 42 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

36% more call options, than puts

Call options by funds: $136K | Put options by funds: $100K

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

2% less funds holding

Funds holding: 133131 (-2)

10.32% less ownership

Funds ownership: 64.35%54.03% (-10%)

17% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 42

50% less capital invested

Capital invested by funds: $93.1M → $46.5M (-$46.6M)

Holders
131
Holders Change
-2
Holders Change %
-1.5%
% of All Funds
1.76%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
18
Increased
35
Reduced
42
Closed
19
Calls
$136K
Puts
$100K
Net Calls
+$36K
Net Calls Change
-$28K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$5.79M -$283K -217,751 -3%
P
2
Pfizer
New York
$4.28M
Vanguard Group
3
Vanguard Group
Pennsylvania
$4.13M -$56.4K -43,413 -1%
KCM
4
Kynam Capital Management
New Jersey
$2.99M +$1.12M +863,000 +36%
PHS
5
PFM Health Sciences
California
$2.29M -$1.78M -1,370,027 -35%
SSA
6
Schonfeld Strategic Advisors
New York
$2.15M +$310K +238,310 +11%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$1.88M +$106K +81,534 +4%
State Street
8
State Street
Massachusetts
$1.5M -$21.3K -16,380 -1%
Two Sigma Advisers
9
Two Sigma Advisers
New York
$1.38M +$47.4K +36,500 +2%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$1.33M -$243K -187,107 -11%
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$1.32M +$304K +234,052 +19%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$1.26M -$452K -347,709 -20%
Bank of America
13
Bank of America
North Carolina
$1M -$869K -668,828 -38%
Two Sigma Investments
14
Two Sigma Investments
New York
$896K -$179K -137,398 -12%
Goldman Sachs
15
Goldman Sachs
New York
$751K -$322K -247,696 -23%
Millennium Management
16
Millennium Management
New York
$750K -$50.4K -38,774 -5%
JP Morgan Chase
17
JP Morgan Chase
New York
$735K -$2.2M -1,691,368 -68%
PFCS
18
Pale Fire Capital SE
Czech Republic
$718K +$68.3K +52,518 +7%
DekaBank Deutsche Girozentrale
19
DekaBank Deutsche Girozentrale
Germany
$666K
Charles Schwab
20
Charles Schwab
California
$664K -$24.1K -18,504 -2%
Northern Trust
21
Northern Trust
Illinois
$605K -$68.5K -52,694 -7%
MC
22
Maverick Capital
Texas
$596K
Cambridge Investment Research Advisors
23
Cambridge Investment Research Advisors
Iowa
$559K +$796K +612,412 New
UBS Group
24
UBS Group
Switzerland
$532K +$242K +186,511 +47%
AQR Capital Management
25
AQR Capital Management
Connecticut
$480K +$602K +463,391 +742%

CRBU Hedge Fund Activity: Q1 2025 in Review

131 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q1 2025, worth a combined $46.5M — down 50% from $93.1M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of CRBU and 18 opened new positions — a net loss of 1 holder — while 42 trimmed existing stakes and 35 added.

The largest buyer was Kynam Capital Management, adding an estimated $1.12M. The largest seller was Morgan Stanley, cutting an estimated $2.95M.

  • 131 institutional investors held Caribou Biosciences (CRBU) as of Q1 2025, down from 133 in Q4 2024.
  • Funds reported $46.5M of Caribou Biosciences stock for Q1 2025, down 50% quarter-over-quarter.
  • 18 funds opened new Caribou Biosciences positions in Q1 2025 and 19 closed out, a net change of -1 holder.
  • The largest Caribou Biosciences buyer in Q1 2025 was Kynam Capital Management, an estimated $1.12M added.
  • The largest Caribou Biosciences seller in Q1 2025 was Morgan Stanley, an estimated $2.95M sold.

Based on aggregated 13F filings for Q1 2025.